TY - JOUR
T1 - Pharmacotherapies for Post-Bariatric Weight Regain
T2 - Real-World Comparative Outcomes
AU - Gazda, Chellse L.
AU - Clark, John D.
AU - Lingvay, Ildiko
AU - Almandoz, Jaime P.
N1 - Funding Information:
IL reports grants, personal fees, and nonfinancial support from Novo Nordisk; grants, personal fees, and nonfinancial support from Sanofi; personal fees and nonfinancial support from Eli Lilly; personal fees and nonfinancial support from Astra Zeneca; personal fees and nonfinancial support from Boehringer Ingelheim; personal fees and nonfinancial support from Janssen; personal fees from TARGETPharma; personal fees from Valeritas; personal fees from Zealand; personal fees from Intarcia; personal fees from Mankind; grants and nonfinancial support from Merck; grants and nonfinancial support from Pfizer; grants from Mylan; personal fees from Intercept; and personal fees from Bayer, all outside the submitted work. CLG, JDC, and JPA have nothing to disclose.
Funding Information:
The authors thank Ms. Bhavini Nayee for assistance with EHR data retrieval and analysis. Parts of this study were presented in virtual poster form at the 80th Scientific Sessions of the American Diabetes Association, June 12, 2020.
Publisher Copyright:
© 2021 The Obesity Society
PY - 2021/5
Y1 - 2021/5
N2 - Objective: This study aimed to compare outcomes of treatment strategies for weight regain after bariatric surgery. Methods: This is a retrospective analysis of 207 individuals treated for post-bariatric weight regain at an academic center from January 1, 2014, through November 25, 2019. Percentage body weight loss was compared after 3, 6, 9, and 12 months of treatment among an intensive lifestyle modification (ILM) group, a non–glucagon-like-1 receptor agonist (GLP-1-RA)-based weight-loss pharmacotherapy (WLP) group, and a GLP-1-RA-based WLP group (the latter two groups in conjunction with ILM). Results: The percentage body weight loss was significantly different between groups after 3 months (1.4% vs. 2.2% vs. 4.5% [P < 0.001] for ILM, non–GLP-1-RA-based WLP, and GLP-1-RA-based WLP groups, respectively), 6 months (0.8% vs. 2.9% vs. 6.7% [P < 0.001]), and 9 months (−1.6% vs. 5.6% vs. 6.9% [P = 0.007]). There was a significant difference in the percentage of individuals achieving ≥5% weight loss after 3, 6, and 9 months, with most occurring in the GLP-1-RA-based WLP group. In a multiple regression analysis including bariatric surgery type, treatment group was the only significant predictor of percentage weight change. Conclusions: GLP-1-RA-based WLP therapies were found to be more effective for treating post-bariatric weight regain than non–GLP-1-RA-based WLP or ILM, regardless of surgery type.
AB - Objective: This study aimed to compare outcomes of treatment strategies for weight regain after bariatric surgery. Methods: This is a retrospective analysis of 207 individuals treated for post-bariatric weight regain at an academic center from January 1, 2014, through November 25, 2019. Percentage body weight loss was compared after 3, 6, 9, and 12 months of treatment among an intensive lifestyle modification (ILM) group, a non–glucagon-like-1 receptor agonist (GLP-1-RA)-based weight-loss pharmacotherapy (WLP) group, and a GLP-1-RA-based WLP group (the latter two groups in conjunction with ILM). Results: The percentage body weight loss was significantly different between groups after 3 months (1.4% vs. 2.2% vs. 4.5% [P < 0.001] for ILM, non–GLP-1-RA-based WLP, and GLP-1-RA-based WLP groups, respectively), 6 months (0.8% vs. 2.9% vs. 6.7% [P < 0.001]), and 9 months (−1.6% vs. 5.6% vs. 6.9% [P = 0.007]). There was a significant difference in the percentage of individuals achieving ≥5% weight loss after 3, 6, and 9 months, with most occurring in the GLP-1-RA-based WLP group. In a multiple regression analysis including bariatric surgery type, treatment group was the only significant predictor of percentage weight change. Conclusions: GLP-1-RA-based WLP therapies were found to be more effective for treating post-bariatric weight regain than non–GLP-1-RA-based WLP or ILM, regardless of surgery type.
UR - http://www.scopus.com/inward/record.url?scp=85103402382&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103402382&partnerID=8YFLogxK
U2 - 10.1002/oby.23146
DO - 10.1002/oby.23146
M3 - Article
C2 - 33818009
AN - SCOPUS:85103402382
SN - 1930-7381
VL - 29
SP - 829
EP - 836
JO - Obesity
JF - Obesity
IS - 5
ER -